Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6413MR)

This product GTTS-WQ6413MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6413MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6673MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ9424MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ6615MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ4250MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ10162MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ7935MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ15752MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ8054MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA h2H12ec
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW